Current Studies

Here is a list of some of our current studies. For additional studies, please visit RecruitMe.

  • The purpose of this study is to learn more about how individuals with OCD respond to a stress reactivity task. This study may help us to better understand the brain basis of OCD so that we can improve OCD treatments. You will be asked to complete a stress reactivity task and questionnaires about your symptoms and health for compensation of up to $100.
  • The purpose of this study is to examine the effect of dietary flavanols on brain activity.Flavanols represent a specific group of plant-derived nutrients that are found in cocoabeans, grapes, tea, berries and various other fruits and vegetables. The specificflavanols investigated in this study come from cocoa. You are being asked toparticipate because you are a healthy subject between the age of 50 and 69 years old.
  • This long-term goal in this study is to reduce the number of patients who develop symptoms of chronic Lyme disease (also known as Post-treatment Lyme Syndrome) by identifying better tests and by understanding the immunologic, rheumatologic, and neurologic impact of this illness over time. This can only be done by comparing those patients who recover fully to those who experience ongoing symptoms, as well as to healthy controls. While at the Center, we will collect blood and conduct very careful clinical assessments.
  • This NIMH-funded research study examines whether there are differences in the brain when people with eating disorders make decisions about food. We hope to understand the neurobiology of eating disorders so that we can improve treatment. Participation includes computer tasks, brain imaging (MRI), and a measure of eating behavior. Eligible individuals will receive inpatient or outpatient treatment at no cost.
  • This is a pre-marketing (Phase 2A) multi-site study of an investigational drug, ganaxolone, as a potential treatment for non-psychotic post-partum depression. Eligible subjects who agree by signing informed consent will spend four days on the 5-South Research Unit (5-S) of the New York State Psychiatric Institute. For 6 hours they will have an tube in a vein into which randomly assigned intravenous ganaxolone or placebo will be infused. Mood and adverse events will be assessed throughout their 5-S stay and at weeks 1, 2, 3 and 4.
  • Healthy heroin users (men and women, ages 21-59) are needed for an eight-week inpatient study investigating medication effects at the NY State Psychiatric Institute. Earn approximately $6,550 - $7,350.
  • A research study at the New York State Psychiatric Institute and Columbia University Medical Center is looking for healthy teens between the ages of 14 and 18 years to participate in a study about food. Come in to the lab three times over the course of two years and get up to $250 each time for your participation. For more information and to see if you are eligible, call the Columbia Center for Eating Disorders at 646 774 8066.
  • This research study uses brain imaging to explore the biological causes of depression and suicidal behavior. The investigators hope to develop a better understanding of how people who attempt suicide differ from those who don't in order to improve prevention. Participation includes brain imaging scans (MRI and PET), neuropsychological tasks and clinical assessment. Eligible individuals will be compensated up to $475.
  • This research study uses brain imaging to explore the biological causes of major depression and why some people feel suicidal or may act on such thoughts. The investigators hope to develop a better understanding of how people who feel depressed and suicidal cope with their feelings to improve treatment and prevention. Individuals may qualify if they have depression with or without suicidal thoughts or any history of suicide attempts. Participation involves a detailed diagnostic set of interviews, brain imaging scans (MRI and PET) and neuropsychological tasks.
  • In this research study, you will receive a medication called carbidopa/levodopa (Sinemet). This medication is approved by the Food and Drug Administration for the treatment of Parkinson's Disease.We are using carbidopa/levodopa off-label in this study to see whether it is capable of improving depressive symptoms as well as mental and physical slowing that occur as people age.